What are the criteria for staging Hepatocellular Carcinoma (HCC)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Hepatocellular carcinoma (HCC) should be staged using the Barcelona Clinic Liver Cancer (BCLC) staging system, which is the most widely accepted approach and has been extensively validated 1.

Staging Criteria

The BCLC system classifies HCC into five stages: 0 (very early), A (early), B (intermediate), C (advanced), and D (terminal). This system considers tumor characteristics (size, number, vascular invasion), liver function (using Child-Pugh classification), and patient performance status.

Key Components of the BCLC Staging System

  • Tumor characteristics: size, number, vascular invasion
  • Liver function: Child-Pugh classification
  • Patient performance status: Eastern Cooperative Oncology Group (ECOG) performance status

Importance of Staging

Proper staging is crucial as it guides treatment decisions, with early stages (0-A) potentially eligible for curative treatments like resection, transplantation, or ablation, while advanced stages may require systemic therapies or palliative care.

Multidisciplinary Approach

The staging process should be performed by a multidisciplinary team including hepatologists, oncologists, radiologists, and surgeons for optimal management 1.

Diagnostic Evaluation

To stage HCC properly, patients should undergo:

  • Contrast-enhanced imaging studies such as CT or MRI to assess tumor size, number, and vascular invasion
  • Laboratory tests to evaluate liver function (albumin, bilirubin, INR) and tumor markers (AFP)
  • Assessment of portal hypertension and performance status completes the evaluation.

Treatment Allocation

Treatment stage migration concept applies, and refinement of BCLC classes by clinical data, molecular classes, or biomarker tools should further facilitate understanding of outcome data, treatment allocation, and trial stratification 1.

From the Research

Criteria for Staging Hepatocellular Carcinoma (HCC)

The staging of HCC is based on several factors, including:

  • Tumor status, defined by tumor size and number, presence of vascular invasion, and extrahepatic spread 2
  • Liver function, defined by the Child-Pugh's class 2
  • Patient performance status, defined by the Eastern Cooperative Oncology Group scale 3
  • Presence of symptoms 2

Staging Systems

Several staging systems are used for HCC, including:

  • Barcelona Clinic Liver Cancer (BCLC) staging system, which is considered one of the best staging systems for HCC 2
  • European systems, such as the French staging system and the cancer of the liver Italian program (CLIP) 2
  • Asian systems, such as the Okuda staging system, Japan integrated Staging (JIS), Tokyo score, and Chinese University Prognostic Index (CUPI) 2

BCLC Staging System

The BCLC staging system is a widely used and well-validated system that incorporates tumor status, liver function, and patient performance to stage patients with newly diagnosed HCC 4. The system is as follows:

  • Stage 0: very early HCC, with a single tumor less than 2 cm in size, and well-preserved liver function 5
  • Stage A: early HCC, with a single tumor or up to 3 nodules less than 3 cm in size, and well-preserved liver function 5
  • Stage B: intermediate HCC, with large or multinodular HCC, well-preserved liver function, and no cancer-related symptoms or evidence of vascular invasion or extrahepatic spread 6, 5
  • Stage C: advanced HCC, with vascular invasion or extrahepatic spread, and poor liver function 5
  • Stage D: terminal HCC, with very poor liver function and severe cancer-related symptoms 5

Assessment of Extrahepatic Spread

The assessment of extrahepatic spread in HCC can be done with either PET/CT or a combination of CT (Chest and abdomen) and a bone scan 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.